Sepsis And Septic Shock Treatment Market are growing at a CAGR of 6.1%.
Sepsis is a potentially life-threatening complication due to infection and the systemic inflammatory response; an overwhelming immune response to infection causes it. Sepsis is treated as a medical emergency, and a severe case of sepsis may lead to septic shock, in which blood pressure reduces dramatically. It is estimated that the sepsis and septic shock treatment market will show significant market growth over the forecast period primarily due to the growing number of the target population, higher number of unmet needs, advancement in sepsis assessment techniques, and presence of novel pipeline therapeutics.
The “Sepsis and Septic Shock Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2017–2025” included an in-depth analysis of the sepsis and septic shock market from 2015 to 2025. This market report includes a detailed study of market segments based on treatment types such as antimicrobial therapy (antibacterial drugs, antiviral drugs, and antifungal drugs) and adjunctive therapy (mechanical ventilation, vasopressor therapy, fluid therapy, corticosteroids, blood transfusion, dialysis, and insulin therapy).
For the geographical study, the global sepsis and septic shock treatment market is categorized based on key regional markets such as North America, Europe, Latin America, Asia Pacific and the Middle East, and Africa. For further regional and country-level analysis, the sepsis and septic shock treatment market is categorized into the United States, Canada, Germany, United Kingdom, rest of Europe, Brazil, Mexico, Rest of LATAM, China, Japan, rest of APAC, GCC and rest of MEA.
Along with statistical information, in-depth qualitative information assessment tools are included in this study to better understand the general market situation and future prospects. For an understanding of ongoing trends of the market and future market scenario, detailed information regarding pipeline analysis, market drivers, challenges, and opportunities in the global sepsis and septic shock treatment market are included in the report. In addition, an attractive investment proposition and company profiling section are also included in this report to provide in-depth information about the key players involved in sepsis and septic shock R&D activities.
It is expected that the global sepsis and septic shock treatment market will show lucrative market growth majorly due to the rising number of the affected population, technological development in sepsis assessment, increase in research and development for developing sepsis treatments, and expected launch of novel pipeline molecules over the forecast period. It is studied that antibacterial drugs among the antimicrobial therapies are the significant revenue generating segment and are anticipated to show the fastest market growth during the forecast period. Because bacteria such as Staphylococcus and Escherichia coli are the most common causes of sepsis. Furthermore, the expected launch of pipeline drugs such as MDX 1105, CYT-107, ALT-836, LB-1148, IFX-1, etc., would assist the market growth of sepsis drugs during the forecast period. Broad-spectrum antibiotics are preferably used to initiate treatment as these are effective against a variety of bacteria. Currently, there is no approved regimen specific to treating sepsis, but antimicrobials and adjunctive therapies are used to treat and manage sepsis. Previously, activated drotrecogin alfa (Xigris) was approved for sepsis but has been voluntarily withdrawn by Eli Lilly in 2011 due to lack of efficacy.
Sepsis is a clinical condition caused by overwhelming inflammatory response to infection leading to multiple organ dysfunction. According to the Centers for Disease Control and Prevention (CDC), more than 1.5 million people are affected with sepsis in the United States; 250,000 Americans die every year. It is observed that among the considered geographical markets, North America is currently dominating the global sepsis and septic shock treatment market, and the United States mainly drives the growth. Early diagnosis of disease, availability of developed techniques for sepsis assessment, wide accessibility to therapeutics, favorable government reimbursement policies, higher cost of therapeutics, and well-developed healthcare infrastructure are the essential factors that favor the market dominance of North America. On the other hand, the sepsis and septic shock treatment market in the Asia Pacific will show the fastest market growth over the forecast period due to developing healthcare infrastructure, rising number of the affected population, and increasing penetration of key players in emerging countries such as China and India.
Sepsis And Septic Shock Treatment Market are growing at a CAGR of 6.1%.
Sepsis And Septic Shock Treatment Market Size will be $XX Billion.
Sepsis treatment costs around $15000 to $40000 in 2020.
Sepsis antibiotic treatment duration is in between 6 to 10 days.
Adrenomed AG, Altor BioScience Corporation, Asahi Kasei Pharma, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, InflaRx GmbH, Inotrem SA, Pfizer Inc., and others.
Report Attribute | Details |
---|---|
Market Value in 2021 | $XX Billion |
Market Value in 2028 | $XX Billion |
CAGR | 6.1% |
Benchmarking Year | 2021 |
Past data | 2017-2021 |
Forecast period | 2017 – 2025 |